Indian drug regulator approves world's first DNA vaccine against COVID-19 for emergency use
The company plans to annually produce up to 120 million doses of the second Indian vaccine of its own production. Previous DNA vaccines have worked well in animals, but not in humans.
India has already administered more than 570 million doses three earlierof approved vaccines - Covishield, Covaxin and Sputnik V. About 13% of adults have been fully vaccinated, and 47% have received at least one vaccine since the campaign began in January.
One vaccine can be created against all coronaviruses
Cadila Healthcare said it has conducted the largest clinical trial of a vaccine in India to date, involving 28,000 volunteers in more than 50 centers.
The company also said that for the first time a vaccine againstCOVID-19 has been tested on young people in India - 1,000 people in the 12-18 age group. The vaccine was rated “safe and very well tolerated” in this age group.
The key third phase of clinical trials wascarried out at the peak of the second wave of the virus. The vaccine manufacturer believes this has confirmed the "efficacy of the vaccine against mutant strains," especially the highly infectious Delta variant.
Read more
Giant iceberg A74 collides with the coast of Antarctica
Two new dinosaur species discovered in China
What is the Kessler effect, and also when and what will the collision of satellites in orbit lead to?